What is it about?

Pre-intervention CT imaging-based biomarkers, such as hyperdense middle cerebral artery sign (HMCAS) may have a role in acute ischaemic stroke prognostication. However, the clinical utility of HMCAS in settings of reperfusion therapy and the level of prognostic association is still unclear. This meta-analysis investigated the association of the HMCAS sign with clinical outcomes and its prognostic capacity in acute ischaemic stroke patients treated with reperfusion therapy.

Featured Image

Why is it important?

This study demonstrated that pre-treatment HMCAS increases the risk of poor functional outcomes. However, its prognostic sensitivity and specificity in predicting long-term functional outcome, mortality and sICH after reperfusion therapy are poor.

Read the Original

This page is a summary of: Prognostic capacity of hyperdense middle cerebral artery sign in anterior circulation acute ischaemic stroke patients receiving reperfusion therapy: a systematic review and meta-analysis, Acta Neurologica Belgica, June 2021, Springer Science + Business Media,
DOI: 10.1007/s13760-021-01720-3.
You can read the full text:



The following have contributed to this page